Evidence map›Paper›PMID 30054487›Full record

ReviewExperimental & molecular medicine2018

ARD1/NAA10 acetylation in prostate cancer.

Katherine J Kuhns, Guanyi Zhang, Zehua Wang, Wanguo Liu

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Experimental & molecular medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
0.5field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 37 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Neuroanatomical features of NAA10 and NAA15-related neurodevelopmental syndromes.Journal of neuroradiology = Journal de neuroradiologie · 2025
    Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Review
  12. Tetrandrine for Targeting Therapy Resistance in Cancer.Current topics in medicinal chemistry · 2024
    Review
  13. The epigenetic function of androgen receptor in prostate cancer progression.Frontiers in cell and developmental biology · 2023
    Review
  14. Article
  15. Review
  16. Review
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Katherine J KuhnsDepartment of Genetics, Stanley S. Scott Cancer Center, Louisiana State University Health Sciences Center, New Orleans, LA, 70112, USA.
Guanyi ZhangDepartment of Genetics, Stanley S. Scott Cancer Center, Louisiana State University Health Sciences Center, New Orleans, LA, 70112, USA.
Zehua WangDepartment of Genetics, Stanley S. Scott Cancer Center, Louisiana State University Health Sciences Center, New Orleans, LA, 70112, USA.
Wanguo LiuDepartment of Genetics, Stanley S. Scott Cancer Center, Louisiana State University Health Sciences Center, New Orleans, LA, 70112, USA. wliu2@lsuhsc.edu.
Louisiana State University Health Sciences Center New Orleans · US

Funding

Training CoreP20MD004817 · NIMHD · DILLARD UNIVERSITY · PI SOTHERN, MELINDA S · 2010 to 2014
$6.3M
DNA Damage-Response Defects in Prostate Cancer RiskR01CA115555 · NCI · LSU HEALTH SCIENCES CENTER · PI LIU, WANGUO · 2007 to 2010
$1.5M
AR-V7 Acetylation in Castration Resistant Prostate CancerR21CA223119 · NCI · LSU HEALTH SCIENCES CENTER · PI LIU, WANGUO · 2018 to 2019
$356k
Germline Mutations in African American Families with Aggressive Prostate CancerR21CA185213 · NCI · LSU HEALTH SCIENCES CENTER · PI LIU, WANGUO · 2015 to 2016
$349k
ARD1-dependent Androgen Receptor Signaling in Prostate CancerR21CA190931 · NCI · LSU HEALTH SCIENCES CENTER · PI LIU, WANGUO · 2015 to 2016
$349k
NCI NIH HHS R01 CA115555NCI NIH HHS R21 CA185213NCI NIH HHS R21 CA190931NCI NIH HHS R21 CA223119NIMHD NIH HHS P20 MD004817
6 · The paper itself

Abstract

Prostate cancer (PCa) is the second most common cancer in men. Androgen receptor (AR) signaling pathway plays a crucial role in prostate development and homeostasis. Dysregulation of this pathway activates AR leading to PCa pathogenesis and progression. AR binds testosterone and other male hormones, which then undergoes post-translational modification for AR nuclear translocation and transcriptional activation. AR activation by post-translational modification is thus imperative for PCa cell growth and survival. Identification and understanding of the pathological and mechanistic roles of AR modifications may increase our understanding of AR activation in PCa and provide new therapeutic options. Recently, AR acetylation has been described as an important step for AR activation. Upregulation of several acetyltransferases has been reported to be associated with PCa progression. Herein, we provide a general understanding of AR acetylation, with a special emphasis on ARD1, and potential therapies that may be exploited against the ARD1-AR axis for PCa treatment.

Indexed as

AcetylationAnimalsHumansMaleN-Terminal Acetyltransferase AN-Terminal Acetyltransferase EProstatic NeoplasmsProtein Processing, Post-TranslationalReceptors, AndrogenNAA10 protein, humanN-Terminal Acetyltransferase AN-Terminal Acetyltransferase EReceptors, Androgen

Identifiers

PMID30054487
PMCPMC6063848
OpenAlexW2884617552

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.